Author: Jessica Yingling

Inside Precision Medicine: Asked & Answered with Artiva’s CMO Dr. Subhashis Banerjee

by on June 2, 2025

Inside Precision Medicine spoke with Artiva’s Chief Medical Officer, Dr. Subhashis Banerjee, about our clinical development approach for AlloNK® in autoimmune disease. In the Q&A, Dr. Banerjee outlines how we are advancing AlloNK® through a parallel trial strategy, conducting both a Phase 2a basket trial and an investigator-initiated study in the community setting. These trials…

Pharmaceutical Manufacturer Q&A: Artiva Allogeneic NK Cell Therapies for Treating Autoimmune Disease

by on April 28, 2025

In this interview with Pharmaceutical Manufacturer, Artiva CEO Fred Aslan, M.D., discusses the unique advantages of natural killer (NK) cell therapies and the company’s mission to bring scalable, off-the-shelf treatments to patients with autoimmune diseases. The Q&A explores how Artiva’s AlloNK® platform—comprising non-genetically modified, cryopreserved NK cells combined with disease-targeting monoclonal antibodies—could offer a more…

GEN: The Body’s Delta Force: Natural Killer Cells Re-Emerge

by on April 10, 2025

In a new feature published by GEN (Genetic Engineering & Biotechnology News), natural killer (NK) cells are in the spotlight showcasing their potential as the next generation of immunotherapies. This article explores how scientific and technological advances are helping cell therapy developers harness NK cells to expand the reach of cell therapy beyond oncology and…

The Bio Report Podcast: Turning Natural Killers into Off-the-Shelf Therapies for Autoimmune Disease

by on March 5, 2025

NK cells, part of the innate immune system, serve as the body’s first line of defense. These cells can recognize and kill abnormal or infected cells. As therapies, they have the advantage over CAR-T and other cell therapies because they can be used off-the-shelf without undergoing gene editing or other genetic modifications. They also don’t…

Drug Discovery World: Expanding Access to Cell Therapies for Autoimmune Conditions

by on January 28, 2025

DDW Editor Reece Armstrong speaks to Fred Aslan, MD, President and Chief Executive Officer of Artiva Biotherapeutics, about how to scale-up access to cell and gene therapies for patients suffering from autoimmune diseases. The rise of cell therapies in the past decade has led to meaningful clinical responses across both haematological diseases like blood cancer,…

PharmaVoice: Natural Killer Cells, a Rising Alternative to CAR-T Cell Therapy

by on January 27, 2025

Natural killer cells continuously patrol the human body, swiftly eliminating viruses and cancer cells, like sharks in prey-laden waters. Several biotech companies are harnessing the power of these innate immune crusaders in oncology and autoimmune diseases, potentially positioning them as a strong competitor to CAR-T cell therapies. “The advantage of NK cells over a T-cell approach…

PharmaShots: Enhancing Care with NK Cell Therapy

by on November 18, 2024

Fred Aslan from Artiva Biotherapeutics in Conversation with PharmaShots discusses: Immune reset in oncology has been observed with approved autologous CAR-T products. A study published in Nature demonstrated B-cell reconstitution and immune reset in systemic lupus erythematosus (SLE) patients treated with a CD19 autologous CAR-T, showcasing promising potential in autoimmune diseases Artiva’s AlloNK, an allogeneic,…